Analysis of Clinical Efficacy of Ceftazidime and Avibactam Sodium in Patients with Carbapenem-resistant Gram-negative Organisms Infection and Its Influencing Factors
Objective:To analyze the clinical efficacy of ceftazidime and avibactam sodium in patients with carbapenem-resistant gram-negative organisms(CRO)infection and its influencing factors,and provide reference for the clinical use of ceftazidime and avibactam sodium.Methods:48 patients with CRO infection who were admitted to the Second Affiliated Hospital of Soochow University from September 2019 to May 2022 and treated with ceftazidime and avibactam sodium were selected as the research subjects,and the information such as patient's age,gender,infection type and state of pathogenic bacteria,use of antibacterial drugs,other auxiliary treatment operations,treatment outcomes was collected to analyze the clinical efficacy of ceftazidime and avibactam sodium in patients with CRO infection and related influencing factors.Results:Among 48 patients with CRO infection,most of them had multi-site infection(28 cases,58.33%),the infection type was mainly pulmonary infection(29 cases,60.42%),and the pathogenic bacteria were mainly Klebsiella pneumoniae(39 cases,81.25%)and Pseudomonas aeruginosa(21 cases,43.75%);most patients were treated with drug combinations(29 cases,60.42%),and the combined drug was mainly carbapenems(17 cases,58.62%).The treatment outcomes of ceftazidime and avibactam sodium showed that 33 cases(68.75%)were clinically effective,and 15 cases(31.25%)were ineffective.The regression analysis results showed that the treatment failure of patients with CRO infection was related to the infection type,whether patients received continuous renal replacement therapy(CRRT),whether patients had a history of polymyxin exposure a month before treatment,whether carbapenems were combined,and the course of treatment(P<0.05),of which,receipt of CRRT was an independent risk factor for the treatment failure of patients(P<0.05);in terms of liver injury,the treatment with ceftazidime and avibactam sodium did not increase the ALT and AST levels of patients significantly(P>0.05).Conclusion:ceftazidime and avibactam sodium are of great significance in the treatment of patients with CRO infection and can be used as one of salvage treatment options.However,CRRT may interfere with the therapeutic effect of ceftazidime and avibactam sodium,and the usage and dosage of ceftazidime and avibactam sodium can be explored to improve the success rate of treatment.
ceftazidime and avibactam sodiumcarbapenem-resistant gram-negative organismsclinical efficacyinfluencing factors
NETL
NSTL
万方数据
